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Preface
An agreement has been signed by the Dutch Expert Committee on Occupational
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Expert Group for Criteria Documentation of Health Risks from Chemicals (NEG).
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Søderlund at the Norwegian Institute of Public Health, Oslo, Norway and has
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Editorial work and technical editing was performed by Anna-Karin Alexandrie,
Ilona Silins, and NEG’s scientific secretary, Jill Järnberg, all at the National
Institute for Working Life in Sweden.
We acknowledge the Nordic Council for its financial support of this project.
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Abbreviations
CI confidence interval
CNS central nervous system
ED50 effective dose in 50% of population
FDA US Food and Drug Administration
FSH follicle stimulating hormone
GABA γ-aminobutyric acid, gamma-aminobutyric acid
GBL γ-butyrolactone, gamma-butyrolactone
GC gas chromatography
GHB γ-hydroxybutyrate, gamma-hydroxybutyrate, γ-hydroxybutyric acid
HPLC high performance liquid chromatography
IARC International Agency for Research on Cancer
LD50 lethal dose for 50% of the exposed animals at single administration
LH luteinizing hormone
MS mass spectrometry
NOAEL no observed adverse effect level
NTP National Toxicology Program
REM rapid eye movement
SPME headspace solid-phase microextraction
UV-VIS ultraviolet-visible
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11. Introduction
γ-Butyrolactone (GBL) is the cyclic ester of 4-hydroxybutanoic acid. In an
aqueous environment, a pH-dependent equilibrium is established between the
open-chain hydroxycarboxylate anion and the lactone ring. In basic media
γ-hydroxybutyrate (GHB) will predominate while in acid media the lactone
form is favoured.
GBL is used in the synthesis of pyrrolidones, as a solvent for polymers, as an
intermediate in the preparation of the herbicide 4-(2,4-dichlorophenoxy) butyric
acid, as a constituent of paint removers, textile aids, and drilling oil. GBL is also
used in electronics, speciality cleaning, and foundry binders. Although GBL is
used in several industries, occupational exposure data is limited. Low molecular
weight (<C8) lactones occur naturally in berries, fruits, and related alcoholic
beverages at concentrations of less than 1 mg/kg. GBL is also used experimentally
in medical treatment. Due to its euphoric/hallucinogenic properties the abuse of
GBL has increased dramatically the last years.
Most of the toxicity studies with GBL were performed in the 1960s and 1970s
and are often not reported in sufficient detail to allow a scientific evaluation of the
data. These older studies focused mostly on toxicokinetic parameters, acute and
local effects but also to some extent on carcinogenicity. They identified central
nervous system (CNS) as a target organ for acute toxic effects but also eye irrita-
tion was reported. Furthermore, these earlier studies demonstrated that GBL is
extremely rapidly metabolised to GHB in the body. Thus, effects of GHB are of
relevance when assessing possible health effects of GBL to humans. An extensive
assessment of genotoxic effects was available in 1981, indicating that GBL has a
low mutagenic potential (26). A toxicological investigation of GBL focusing
on potential carcinogenic effects, was reported by the National Toxicology
Program (NTP) in 1992 (118). In addition, the recent abuse of GBL has increased
our knowledge of toxic symptoms and their treatment in humans. No reports
describing occupational exposure levels and/or occupational health effects in
humans were located.
2. Substance identification
IUPAC name Dihydro-2(3-H)-furanone
CAS name γ-Butyrolactone
CAS No 96-48-0
EINECS No 202-509-5
Synonyms butyric acid lactone; 1, 2-butanolide; 1, 4-butanolide;
4-butyrolactone; 4-hydroxybutanoic acid lactone;
γ-hydroxybutyric acid cyclic ester; 4-deoxytetronic acid;
tetrahydro-2-furanone
2Trade names BLO; γ-6480; γ-BL; GBL; GHB; Gamma Hydrate;
Gamma-OH; Sotomax; Agrisynth BLO; Agsol ExBLO;
Blue Nitro; Gamma Ram; ReActive; Renewtrient;
Regenerize; Revivarant; Verve
Molecular formula C4H6O2
Molecular weight 86.1
Structural formula O O
3. Physical and chemical properties1
Description Colourless oily liquid with a mild caramel
odour
Melting point -44ºC
Boiling point 206ºC
Vapour pressure 0.15 kPa (at 20ºC)
Vapour density (air = 1) 3.0
Flash point 98ºC (open cup)
Autoignition temperature 455ºC
Explosive limits Upper limit: 16.0 vol %,
Lower limit: 3.6 vol %
Density (d420) 1.1286 g/ml
Refractive index 1.4365 at 20ºC
Solubility in water Miscible with water (freely soluble)
Solubility in organic solvents Soluble in methanol, ethanol, acetone, and
benzene
Partition coefficient logKow = -0.64
pH 4.51 (10 % aqueous solution)
Odour threshold –
Surface tension 4.61 x 10-2 N/m
Viscosity 1.717 x 10-3 m2/s at 25ºC
Conversion factors in air 1 ppm = 3.57 mg/m3
(20ºC, 101,3 kPa) 1 mg/m3 = 0.28 ppm
1References for data (18, 46, 64, 71, 72, 106, 117, 118, 139, 149).
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Figure 1. Hydrolysis of γ-butyrolactone (GBL).
GBL undergoes the usual chemical reactions of γ-lactones, namely hydrolytic
ring opening to form GHB (Figure 1) and reactions in which oxygen is replaced
by another ring heteroatom (e.g. nitrogen or sulphur). GBL is relative rapidly
hydrolysed by bases and slowly hydrolysed by acids (1, 106, 118). Under strongly
alkaline conditions (pH 12) GBL is completely converted to GHB within minutes.
In pure water, GBL forms an equilibrium with GHB of about 2:1 over a period of
months. The same equilibrium was reached within days at pH 2. Heat increases
and refrigeration decreases the rate of of GBL hydrolysis relative to ambient
temperature (20). GHB, when heated, can form GBL. Based on a log octanol-
water partition coefficient (logKow) of -0.64 a bioconcentration factor of 3.2 can
be calculated (quoted from (64)).
4. Occurrence, production and use
4.1 Occurrence
Low molecular weight aliphatic lactones (C<9) occur naturally in berries, fruits
and related alcoholic beverages at concentrations less than 1 mg/kg (1, 71). GBL
has been found in beer (2 mg/l, (148)), apple brandy (5-31 mg/l, (136)), wine
(171), vinegar (81), cooked meat (58, 93), roasted filberts (144), coffee (54), and
tomatoes (77). It has also been detected in tobacco smoke condensate (113) and in
mainstream and sidestream smoke (137).
Data from the Norwegian Product Register (2000) show that GBL occurs in a
total of 134 products at a total of approximately 70 tons per year. Forty-nine
products account for approximately 80% of the tonnage declared to the product
register, with main use as a binder in foundering sand. The total tonnage in
products containing GBL seems to have been more or less constant the last years.
In Sweden the tonnage of GBL in chemical products was: 1996; 270 tons, 1997;
412 tons, 1998; 379 tons, and 1999; 228 tons (export not included) (Swedish
Product Register, 2000).
Small amounts of GBL may be formed in the body and excreted in urine, as
noted in rats following intraperitoneal administration of the nitrosamine N-nitro-
sopyrrolidine (21). GHB, the hydrolysis product of GBL, occurs naturally in small
amounts in mammalian brain. The level in rat brain was approximately 2 nmol/g
wet weight tissue (131). The endogenous effects of GHB are not precisely known,
4but GHB is believed to play a role in neurotransmission and has an effect similar
to that of γ -aminobutyric acid (GABA).
4.2 Production
GBL can be prepared by a variety of methods (83, 106). The method used for
commercial production in the USA is the dehydrogenation of 1,4-butanediol over
a copper catalyst at 200-250ºC (46, 83, 106). GBL can also be produced by
hydrogenation of maleic anhydride (83, 106).
Production of GBL in the USA in 1974 and 1992 was estimated to be 14
million kg and 45 million kg, respectively (72, 118). Information available in
1995 indicated that it was produced in six countries (17).
4.3 Use
GBL is used primarily as a chemical intermediate in the production of all pyrro-
lidones, as an intermediate for other organic chemicals (pesticides, herbicides and
plant growth regulators), and may be formed as an intermediate in the production
of vitamins and pharmaceuticals (9, 71, 72). GBL is an intermediate in the pre-
paration of the herbicide 4-(2,4-dichlorophenoxy) butyric acid. GBL is also used
as a solvent or in the production of: pesticides, photochemical etching, electrolytes
of small batteries and capacitors, viscosity modifiers in polyurethanes, surface
etching of metal coated plastics, organic paint disbursement for water soluble
inks, pH regulators in the dyeing of wool and polyamide fibres, foundry binders
(carrier solvent for the hardener for phenol formaldehyde resins), and curing
agents in many coating systems based on urethanes and amides (9, 71, 72, 106).
GBL serves as intermediate in the manufacture of polymers (based on vinyl-
pyrrolidone) used as clarifying agents in beer and wine (1, 106, 118). Low
molecular weight lactones (<C8) generally exhibit a sweet herbaceous aroma
accompanied by a sweet caramel-like taste and are used as flavouring agents at
levels normally less than 50 mg/kg.
GBL and GHB have been used therapeutically in humans as sedatives and in
the treatment of alcohol dependency (GHB dose: 0.15 g, three times daily or 50
mg/kg body weight, three times daily for 8 weeks) and the opiate withdrawal
syndrome (1, 2, 36). GBL is also being used experimentally in the treatment of
narcolepsy. Thus, GBL appears to have been available only as an investigational
new drug for specific purposes. GHB has been under investigation in the manage-
ment of narcolepsy for about two decades (dose: 4 g given twice during the night)
(36, 141).
US Food and Drug Administration (FDA) banned GBL and GHB for sale as a
food supplement in 1990 due to several cases of intoxication with symptoms like
nausea, uncontrolled shaking, coma, respiratory depression, and even death. The
FDA also called for its voluntary recall. Since the ban, GBL and GHB have been
marketed illegally in the USA to bodybuilders and athletes (108). There are
indications that GBL and GHB can induce sleep related growth hormone secretion
5in humans (160) and have become popular with bodybuilders for “bulking up”
and “building strength”. Furthermore, GBL and GHB have been implicated in an
increasing number of sexual insult cases. Due to their euphoric/ hallucinogenic
properties, the abuse of GBL and GHB has increased dramatically in the USA and
has since 1995 also appeared in Europe, mainly in England but lately also in the
Scandinavian countries (36).
The import of GBL to Sweden has been reported to be in the range of 200-300
tons/year (124).
4.4 Purity
GBL are available in different purity grades, depending on production and
purification. Specifications for a US grade (not specified) of GBL were as
follows: purity; 99.0%, hydroxybutyric acid; max 0.1%, water; max 0.3% (71).
Other impurities reported are: 1,4-butanediol and 1-butanol (46). Traces of
chlorine, sulphate, nitrate, iron, copper, zinc, lead, sodium, and potassium have
been reported in “electronic” grade GBL (99.9% pure) (9). BASF report a
standard grade of 99.7% purity containing a maximum of 0.05% water, 0.10%
1,4-butanediol, and 0.03% acid (w/w) (calculated as butyric acid) (9).
5. Occupational exposure data
Occupational exposure is most likely to occur from dermal contact and inhalation
during production, formulation, and use. The use of GBL as a solvent in electronic
industry and as a chemical intermediate could lead to worker exposure. However,
very limited data describing occupational exposure were located in the literature.
Anundi and co-workers have measured the air concentration of GBL in com-
mercial products used during graffiti removal (5). The air concentration in the
breathing zone ranged from less than 0.01 to 1.1 mg/m3 with an arithmetic mean
of 0.4-0.53 mg/m3 depending on the work task. No analyses of GBL levels in
urine or plasma were performed.
The US National Institute of Occupational Safety and Health (NIOSH) estima-
ted that 5 200 and 44 000 workers were potentially exposed to GBL in 1974 and
1983, respectively (114, 115). The number of different industries and occupations
for these workers increased from 12 and 18 in 1974 to 38 and 42 in 1983. Sixty-
five % of the workers were potentially exposed in printing and publishing and in
textile mill industries in 1983.
6. Measurements and analysis of workplace exposure
Reports concerning industrial hygiene measurements are limited. The analysis of
GBL and GHB is complicated by the small, polar nature of the molecules, which
result in short retention times in high performance liquid chromatography (HPLC)
6with reversed phase columns. The absence of a strong chromophoric group makes
detection by ultraviolet and visible (UV-VIS) spectrometric methods difficult.
Current methods use mass spectrometric (MS) methods involving derivatisation
followed by gas chromatograpy (GC).
Mesmer and Satzger have reported an HPLC/UV-VIS method for separation
and quantification of GBL and GHB (108). The analytical method was developed
to detect GBL and GHB in illegal preparations on the black market but should
also apply to analysis of work place exposures. The detection limit is 50 ng
injected onto the HPLC column. Five µl samples of concentrations of 0.3 mg/ml
of GBL and 0.4 mg/ml GHB were easily detected. They have also reported a
simple and fast HPLC/thermospray MS method for confirmation. The charac-
teristic mass spectrum can be obtained with as little as a 5 µg of the test chemical.
Couper and Logan have reported a simple liquid-liquid extraction procedure
for the analysis of GHB in biological fluids without conversion to GBL (22).
Following derivatisation to its di-trimethylsilane derivative, GHB was detected
using GC/MS with electron ionisation. The quantification limit in blood was 12
µmol/l (1 mg/l) using 1 ml blood.
A fast, simple, and selective method for determination of GHB in blood and
urine by headspace GC/MS has been reported (76). The method is based on the
formation of GBL from GHB using headspace sampling. Analysing is done by
headspace GC with flame ionisation detector or coupled to a MS. The detection
limit is in the low mg/l range.
McCusker and co-workers describe a direct method for analysis of GHB in
human urine (104). The method uses solid-phase extraction, liquid extraction, and
silyl-derivatisation with trimethylchlorosilane followed by GC/MS using deuter-
ated GHB (d6-GHB) as the internal standard. The method was linear from 58-
5 800 µmol/l (5-500 mg/l) and can discriminate between GHB and GBL. This
method, however, is not readily applicable to the analysis of GHB in blood.
GHB has been determined in plasma and urine after it has been converted to
GBL and extracted from the biological fluids together with delta-valerolactone as
an internal standard (40). Final GC/MS analysis is obtained under electron
ionisation, selected ion monitoring conditions. The assay was linear for plasma
concentrations of GHB of 23-2 300 µmol/l (2-200 mg/l) and a urine range of 23-
1 700 µmol/l (2-150 mg/l) (40).
A very sensitive and specific assay for GHB detection in brain tissue has been
reported by Ehrhardt and co-workers (34). GHB was derivatised to give the
corresponding pentafluorobenzyl ester of the N-tert-butyldimethylsilyl derivative
of GHB and analysed using GC/MS with an electron capture detector. The detec-
tion limit was about 5 pg per injection. Although the brain is not suitable for
biomonitoring, the method as such could possibly be adapted for use in blood,
urine, or other tissues more suitable for sampling.
More recently several studies have reported analytical methods to detect GBL
or GBL/GHB in body fluids. Frison and co-workers describe the detection of
GHB, after conversion to GBL, and subsequent headspace solid-phase micro-
extraction (SPME), and detection by gas chromatography/positive ion chemical
7ionisation mass spectrometry (GC/PICI-MS) using deuterated GBL (d6-GBL) as
internal standard (47). The limit of detection for GHB (and GBL since GHB is
converted to GBL) was 0.05 mg/l in plasma and 0.1 mg/l in urine. Human levels
were 0.1-0.5 mg/l in plasma and 0.2-2.0 mg/l in urine.
A similar analytical method as that reported by Frison and co-workers has been
published by LeBeau et al. (90). The limit of detection in this study was 0.5 mg/l,
both in blood and urine. Duer and co-workers have analysed GBL in urine, blood,
ocular fluid and brain (32). In order to analyse GBL, existing GHB is first deter-
mined, GBL is then converted to GHB under acid conditions (pH 4) followed by a
second analysis by GC/MS. In this study γ-valerolactone is used as an internal
standard. The limit of detection was 1.5 mg GHB/l and the limit of quantitation
was 4.9 mg/l. Similar values are anticipated for GBL since a 100% conversion of
GBL to GHB was reported.
Fukui and co-workers have reported a simple GC/MS method for the deter-
mination of GBL in human plasma (48). The plasma sample was spiked with
deuterated GBL, extracted by dichloromethane in acidic conditions, and analysed
by GC/MS.
Nuclear magnetic resonance (NMR) spectroscopy has also been used to identify
and directly quantitate GBL and GBH (19), although the sensitivity is low.
Occupational Safety and Health Administration (OSHA) has briefly described
an analytical method using GC with flame ionisation detection (119). SPME has
been used as a sample concentration technique. SPME combined with GC/MS
have been used in the analysis of volatile flavour compounds (including GBL) in
kiwi fruits (170). Dahlén and Vriesman have described a method using micellar
electrokinetic chromatography (23). The method, however, appears to have a
relatively low sensitivity with a detection limit of 340 mg/l.
7. Toxicokinetics
7.1 Uptake
A skin permeability rate of 1.1 g/m2/hour (0.11 mg/cm2/hour) was reported by
Ursin and co-workers using a Franz diffusion cell and human breast skin with a
thickness of 300 to 600 µm (159).
According to Fasset, GBL appears to be readily absorbed through guinea pig
skin (39). Dermal absorption has been studied in male Sprague-Dawley rats (49).
GBL was applied directly on the shaved abdomen over a 3 x 3 cm area at a dose
of 546 mg/kg body weight or after treatment with 4 ml of thioglycolic acid-based
depilating agent. The maximum plasma concentration was 1.7 µmol/ml and
peaked after 2 hours. The depilating agent increased to some extent the peak
plasma concentration and decreased the time to reach the peak concentration. At
least 10% of the percutaneous dose was absorbed and the plasma concentration
approached the level (4.6 µmol/ml) required for complete hypnosis in rats (49).
8GBL is rapidly and completely absorbed over a wide dose range following oral
administration (7, 49, 60, 92). The oral/intracardial area under the curve (AUC)
ratio in rats dosed with 136 and 546 mg/kg GBL were 0.85 and almost unity,
respectively (92). The peak plasma concentration after dosing is proportional to
the dose at least up to 500-600 mg/kg body weight. In rats, 136 mg/kg and 546
mg/kg GBL gave a plasma concentration of approximately 4 and 17 µmol/ml,
respectively (49, 92). Peak plasma concentrations were reached within 1 hour
after exposure.
Hardly any chemical hydrolysis of GBL will take place under acidic conditions.
Thus, the lactone form will predominate completely in the stomach following oral
administration.
No studies were located describing absorption following inhalation exposure.
7.2 Distribution
GBL is converted to GHB within minutes by enzymatic hydrolysis catalysed by
the enzyme lactonase found in blood and in organs such as the liver (42, 60, 130,
133). It must be assumed that GBL is distributed in the body mainly in the form of
GHB. GHB also occurs normally in mammalian brain. The highest concentrations
of GHB in the human brain are found in the substantia nigra, thalamus and hypo-
thalamus. Ten to fifteen times higher concentrations are found in kidneys, heart,
muscles and fat (36).
7.3 Biotransformation
The initial step in the metabolism of GBL is its conversion to GHB. After
parenteral or oral administration of GBL to rats the parent compound is rapidly
hydrolysed to GHB in blood and liver by lactonase. Other tissues of the rat such
as brain, heart, skeletal muscle, intestine, and cerebrospinal fluid were substan-
tially less capable of enzymatic hydrolysis of GBL. In in vitro studies the half-
time of GBL in rat blood was less than 1 minute (42, 130). For comparison, at pH
7.4 the nonenzymatic hydrolysis half-time of GBL is about 1 000 days (7). In vivo
absorption studies (see section 7.1 Uptake) have shown that GBL is extensively
metabolised to GHB within minutes after absorption. A comparison of human and
rat lactonase activity in serum showed a similar Vmax and a very high Km (1-3x10-2
M) in both species (133). Fishbein and Bessman have reported Vmax values of 2.18
and 17.2 µmol/10 minutes/mg protein for rat liver and human plasma lactonase,
respectively (42). In this study the equilibrium between GBL and GHB in the
presence of lactonase (source not described) was also studied. At pH 7.4 only
1.5% existed as lactone. When increasing the pH above the pKa (i.e. 4.72) more of
the acid will be ionised and unavailable for lactonisation.
The metabolism of GBL has recently been reviewed (1, 118). It appears that the
pathway for GHB metabolism has not been completely characterised, and may
vary either quantitatively or qualitatively depending on plasma levels of GHB
and the organ, i.e. whether it is endogenous GHB in the brain or exogenously
9administrated and metabolised in the liver (118). Below are reported studies that
investigate the further metabolism of GHB. Most of these studies were performed
between 1960 and 1975.
Several pathways have been suggested for the metabolism of GHB, such as its
conversion into succinic acid and other citric acid cycle intermediates (30, 41),
interconversion into GΑΒΑ (31, 101, 134, 163), and breakdown via β-oxidation
(168).
It was originally suggested that GHB is metabolised by entry into the citric acid
cycle. Oxidation of GBL to succinate by alcohol dehydrogenase and succinate
semialdehyde dehydrogenase occurs primarily in the liver. Succinate then parti-
cipates in the citric acid cycle (30, 41, 91, 110). However, when incubating rat
liver homogenate with 14C-GHB only 6% or less of the radiolabel appeared in
succinic acid (130). Furthermore, only a very small proportion of the radiolabel
from [1-14C]- and [4-14C]-GHB administrated intravenously or intraperitoneally
to rats or cats appeared in succinate (133, 168). It is now accepted that linear
aliphatic hydroxycarboxylic acids in general are hydrolysed and rapidly oxidised
via the fatty acid pathway. GHB will form acetyl CoA that enters the citric acid
cycle and ends up as CO2.
Brain slices taken from adult male Wistar rats have been shown to metabolise
GHB to GABA via a transamination mechanism (γ-aminobutyrate-2-oxoglutarate
transaminase) and not through the citric acid cycle (163).
Intermediates of GBL have been detected in human urine after oral admini-
stration of GBL(91). Four humans (two males and two females) were given a
single oral dose of GBL and urine was collected hourly. (S)-3,4-Dihydroxybutyric
acid, glycolic acid and 4-hydroxy-3-oxobutyric acid were present in the urine (91)
(Figure 2). The data strongly support that the GBL metabolism, following its
hydrolysis to GHB, occurs via β-oxidation in humans.
7.4 Excretion
GBL is eliminated primarily as respiratory CO2 and urinary metabolites. In
humans the rate of urinary excretion of GBL metabolites was 1.2 mg/hour in
controls (from dietary and endogenous sources) and 40 mg/hour over a 5-hours
period following an oral dose of 1 000 mg of GBL (91). A relatively short
terminal half-time of 30 minutes for GHB, due to extensive liver metabolism
following oral administration to humans and rats, has been reported (49, 85). The
initial half-time in plasma of GBL following an oral dose of 136 mg/kg body
weight of GBL to rats is about 1 hour and the terminal half-time about 30 minutes
(92). The apparent delayed initial elimination could be due to the rapid oral
absorption rate of GBL resulting in nonlinear kinetics.
In rats, [1-14C] or [4-14C]-GHB given intraperitoneally (500 mg/kg) is excreted
as 14CO2. About two-thirds of the dose was excreted in this manner within 6 hours,
and an additional 10-20% over the next 18 hours. The rate of the oxidation to CO2
suggests a final breakdown via the citric acid cycle. The most likely hypothesis
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Figure 2. Metabolism of γ-butyrolactone (GBL) in humans. Adapted from (1, 91).
for the biological degradation of GHB is via β-oxidation as the primary step,
rather than further oxidation of the terminal hydroxyl group (168).
Following a single intravenous dose of 2 µC 14C-labelled GHB in rats, traces
of 14CO2 could be detected in respiratory air after less than 4 minutes, and a maxi-
mum was reached after 15 minutes. Sixty percent of the total 14C was eliminated
as 14CO2 within 2.5 hours (130, 133). Similar results were obtained with [1-14C]-
GBL. However, the peak of 14CO2 was reached in 20 minutes probably reflecting
the time needed to convert GBL to GHB (133). From this study the overall half-
time of GHB in blood after a 500 mg/kg body weight dose of GBL given
intravenously, can be estimated to be about 45 minutes.
Following intraperitoneal administration of 500 mg/kg body weight of GBL to
rats the concentration of GBL in brain fell from 170 µg/g tissue at 3 minutes to 29
µg/g tissue at 15 minutes post exposure (60). A study by Möhler and co-workers
indicate a half-time of GHB in mouse brain of about 5 minutes following intra-
venous injection of [1-14C]-GHB (dose was not stated) (110).
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8. Methods of biological monitoring
There is no established method for biological monitoring of GBL and GHB.
Several methods for determining concentrations of GHB in blood and urine have
been reported. Some of the methods used to detect GBL and GHB in biological
media are reported in Section 6. Theoretically biological samples will contain
both GHB and GBL. Some analytical methods convert GHB back to GBL by
heating under acid conditions whereas others are able to discriminate between
GBL and GHB. Biological monitoring should ideally take into account both the
levels of GHB and GBL in the body. However, since GBL is enzymatically
converted to GHB, the levels of GHB measured in the body will within a few
minutes after exposure most likely reflect the exposure dose (i.e. GBL). On the
other hand, the relatively short half-time of GHB in blood limits its usefulness
in monitoring. Intermediates of GBL have been detected in human urine after
oral administration of GBL. (S)-3,4-Dihydroxybutyric acid, glycolic acid and
4-hydroxy-3-oxobutyric acid were present in the urine of exposed humans (91).
However, the usefulness of these metabolites in biomonitoring remains to be
shown.
9. Mechanisms of toxicity
The major concern of GBL is its effect on the CNS. However, GBL also causes
eye irritation and may have the potential to induce reproductive toxicity.
GHB induces CNS depression at dose levels that are approximately 100 times
those that occur naturally (endogenously) in the brain. The sedation and stupor
observed in experimental animals by GBL is likely attributed to its principal
metabolite, GHB, or possibly to GABA that can be formed from GHB. GABA
seems to be the major precursor of endogenous GHB in the brain although GHB
formation represents only a minor route of GABA metabolism (57, 118, 134).
It has been suggested that GHB may be involved in synaptic transmission based
on its low and heterogeneous distribution in the brain, extremely rapid turnover
rate (57), the immunocytochemical localisation of the GHB synthesising enzyme
in the brain (172), and high-affinity binding and release (11, 98-100). GHB has
specific binding sites in the brain, where it exerts a GABA-like activity i.e.
inhibits dopamine release (14). The affinity to the specific GHB-receptor is
approximately 1 000 times that of the GABAB-receptor. At physiological
concentrations GHB appears not to have a full agonistic effect on the GABAB-
receptor. GHB does not bind to the GABAA-receptor. Thus, most likely the
pharmacological effects of GBL are directly mediated by GABAB-receptors (13,
80).
Anaesthetic doses of GBL or GHB produce an acute blockage of cell impulse
flow in the nigro-striatal dopaminergic pathway for at least one hour (36, 118,
132, 169). The symptoms of CNS effects of GHB may be explained by an initially
inhibited dopamine response followed by an increased dopamine release. It has
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been suggested that GBL causes an increase in brain dopamine by antagonising
transmitter release from nerve terminals (35). The mechanisms by which GHB
exerts its effects in the brain have, however, not been fully elucidated.
The anabolic characteristic of GHB is correlated to, but not associated with,
an increased level of prolactin. The anabolic effect of GBL seems, however, to
be due to increased sleep-related growth hormone secretion (160). It has been
suggested that the decreased alcohol intake observed following GBL exposure
to rats with a preference to alcohol, is mediated by an inhibition of firing in
dopaminergic neurones (37, 116).
There are indications that GBL may adversely affect reproduction in experi-
mental animals. The inhibitory effect of GBL on ovulation in rats was suggested
to be caused by hormonal effects in CNS resulting in reduced levels of luteinizing
hormone (LH) and follicle stimulating hormone (FSH), and not by a direct effect
of GBL or its main metabolite GHB on reproductive organs (10). However, in a
resent in vitro study by Kubelka and co-workers GBL was shown to arrests
meiotic maturation of bovine oocytes probably by inhibiting the activation of
p53 kinase or mitogen-activated protein kinase (88). This result provides some
evidence for a direct effect on the oocytes.
The mechanism for eye irritation is not known. One could, however, speculate
that the rapid biotransformation of GBL to GHB and the resulting equilibrium
between the acid and the anion may be a contributing factor.
10. Effects in animals and in vitro systems
10.1 Irritation and sensitisation
In a review paper, undiluted GBL is quoted not to cause skin irritation after a 20-
hour application to the skin of the back of white rabbits (18). In an older study,
GBL induced some skin irritation in the guinea pig (39). The details given in these
studies do not allow a grading of the response according to current used grading
systems. Altogether it appears that GBL has a weak skin irritation potential.
In an eye irritation test, lesions were observed in the cornea, iris, and conjunc-
tiva after instillation of undiluted GBL in the conjunctival sac. The reported
damage to the cornea and iris was reversible (quoted in (18)). GBL was evaluated
to be an ocular irritant in an in vitro bovine corneal opacity test (52, 53). The
effect was completely reversible after 14 days (53). GBL was also positive in the
hen's egg test-chorioallantoic membrane (HET-CAM) assay, which can detect
potential in vivo irritant effects on the conjunctiva (55, 56). The available
information with respect to GBL-induced eye irritation is limited and based
mostly on older studies supported by new in vitro assays. However, these studies
show that GBL is an experimental eye irritant that apparently does not lead to
permanent eye damage. The eye irritant effect of GBL is likely to be expressed
also in humans.
13
In guinea pigs, no indications of a skin sensitising effect were seen in tests not
described in more detail (quoted from (39)). However, the substituted GBLs,
α-methyl-γ,γ-dimethyl GBLs and α-methylene-GBL (tulipalin), are skin
sensitizers (45, 105). The present toxicological information does not allow an
evaluation of GBL skin sensitisation potential.
10.2 Effects of single exposure
Data on the lethal dose for 50% of the exposed animals at single administration
(LD50) of GBL is summarised in Table 1. Most of the studies available were
performed between 1960 and 1970 and used oral administration. No clinical signs
of toxicity following oral administration were reported other than dose-related
anaesthetic effects, characterised by loss of righting reflex (62, 89).
From Table 1 it is concluded that GBL has a moderate to low acute toxicity in
laboratory animals. The dermal LD50 in guinea pigs is considerable higher than the
oral LD50 (39).
In a study by Monsanto Corporation, Sprague-Dawley rats were exposed by
inhalation to 5 100 mg/m3 of GBL for 4 hours (83% of the particles measured 10
microns or less). No deaths occurred during treatment or the 14-day post-exposure
observation (111). Rats exhibited of toxicity prostration, lethargy, shallow
breathing, limb disuse, and clear discharge from the nose. The effects were clearly
reversible. No treatment-related pathological effects were found at terminal
necropsy (111).
Low doses of GBL (intraperitoneally or intravenously: 100 or 200 mg/kg) have
a biphasic effect on locomotor activity in the rat (1, 25). The acute toxicity of
GBL by intraperitoneal administration was also studied in male white mice (strain
R3), and in male Wistar rats. Each dose was injected to 5-8 animals. The LD50
for mice was 1 100 mg/kg, and that for rats was 1 000 mg/kg. GBL caused
anaesthesia in both species. Doses of GBL above 200 mg/kg almost completely
abolished motility in mice and rats. Respiration was markedly slowed and
increased in amplitude, reactions to acoustic stimuli were weaker or abolished
while reactions to pain stimuli and righting reflex were maintained. Doses of 400
or 500 mg/kg in mice abolished the righting reflex already after 5 minutes without
affecting pain reflexes. In rats, the same doses produced deep sleep with loss of
righting reflex and pain reflexes. Doses above 800 mg/kg in both species induced
Table 1. Acute toxicity of GBL in different species.
Species Route of
administration
LD50 (mg/kg)   Reference
Rat oral 1 800 (89)
Mouse oral 1 260 (62)
Mouse oral 1 245 (140)
Mouse oral 800-1 600 (39)
Guinea pig oral 500-700 (46)
Guinea pig dermal Approx. 5 600 (39)
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deep anaesthesia in which animals died after several hours as a result of respira-
tory paralysis (146). Intraperitoneal administration of 150-200 mg/kg body weight
of GBL to adult Sprague-Dawley rats resulted in immobilisation of the animals
and staring behaviour. In infant or young rats, 50 mg/kg body weight (lower doses
were not tested) GBL induced behavioural arrest with staring and limb extension
(152).
10.3 Effects of short-term exposure
In a study by Nowycky and Roth, the effect of repeated exposure on the CNS was
studied in rats (116). Sprague-Dawley rats were given a 1% solution of GBL
(about 3 000 mg/kg body weight) in the drinking water for 3 to 4 weeks and then
given a single intraperitoneal injection of 350 or 750 mg/kg body weight of GBL.
The rats developed a tolerance to the behavioural effects of GBL (measured as
duration of loss of righting reflex after a challenge dose of GBL and to elicit
increased dopamine synthesis). The four weeks exposure caused only a slight but
significant reduction in weight gain in male rats.
F344/N rats and B6C3F1 mice (5 animals per dose and sex) received GBL in
corn oil by gavage for 12 consecutive days, excluding weekends (i.e. 16-day
study) (118). The daily doses were 0, 75, 150, 300, 600 or 1 200 mg/kg body
weight in rats and 0, 87, 175, 350, 700 or 1 400 mg/kg in mice (Table 2). Com-
plete necropsies were performed on all animals. All rats receiving 1 200 mg/kg
GBL died within the first 3 days of exposure. One male receiving 600 mg/kg died
on day 3. There were no significant differences between the final mean body
weights of male rats administered GBL and controls. The mean body weight gain
of the female rats given 600 mg/kg was significantly lower than in controls. The
mean body weight gains of female rats given 300 mg/kg or less and all male rats
were similar to those of the controls. Rats in the 600 and 1 200 mg/kg groups
became recumbent or inactive with irregular and laboured respiration soon after
dosing (118). All male mice and 4 female mice receiving 1 400 mg/kg died before
the end of the study. Mean body weight gains of dosed mice were similar to those
of controls. Mice receiving a dose of 350 mg/kg or more became recumbent or
inactive shortly after dosing. Some mice also exhibited irregular respiration or
dyspnea (118).
10.4 Effects of long-term exposure and carcinogenicity
In connection with the 2-year NTP bioassay F344/N rats and B6C3F1 mice (10
animals per dose and sex) were dosed with GBL by gavage for 90 days (118).
The doses were 0, 56, 112, 225, 450, or 900 mg/kg body weight in rats and 0, 65,
131, 262, 525, or 1 050 mg/kg in mice, 5 days/week (Table 2). All animals were
observed twice a day and clinical observations were recorded once a week.
Necropsy was performed on all animals and the following organs were weighed:
brain, heart, right kidney, liver, lung, and thymus. Complete histopathology was
carried out on all animals that died or were killed moribund during the study, all
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controls, the 900 mg/kg rat group, the 450 mg/kg male rat group and 1 050 mg/kg
mice group. The study was conducted in compliance with the FDA Good
Laboratory Practice (GLP). All male rats and one female rat given 900 mg/kg
GBL died by week 8. The final body weights and body weight gains of males in
the 450 mg/kg group were significantly lower than those of the controls but
unaffected in males at lower doses and in females at all doses. All rats in the 900
mg/kg rat dose groups became recumbent within several minutes after dosing,
but appeared normal later. Rats in the 225 and 450 mg/kg dose groups exhibited
slight inactivity after dosing. However, after 2 to 3 weeks an adaptation to this
anaesthetic effect occurred. At necropsy no significant biological differences in
absolute or relative organ weights between exposed and control rats were noted
and no gross lesions related to GBL exposure were reported. Increased incidences
of inflammation of nasal mucosa were noted in some dose groups but are likely to
be related to the reflux of the gavage solution into nasopharynx after dosing. The
significance of the mice study is somewhat reduced due to a relative high number
of deaths due to improper gavage technique. Deaths related to GBL administration
occurred in three male and one female mice from the 1 050 mg/kg dose group.
Except for 11% lower mean body weights of male mice in the 1 050 mg/kg dose
group, no reduced final mean body weight was detected in the other dose groups
compared to controls. As with rats an adaptive response to the anaesthetic effect
of GBL was reported in mice given 525 mg/kg or less. There were no biologically
significant differences in absolute and relative organ weights between exposed
and control mice. No gross or microscopic lesions related to GBL administration
were observed (118).
Among the 12 male weanling albino rats given a total of 4 doses ranging from
200 to 900 mg/kg of GBL by gavage during a 7.5 months period, the ones that
received amounts in excess of 700 mg/kg died within a few days from respiratory
failure and lung congestion (142). Animals that died showed degenerative lesions
and calcifications of the heart and kidneys. However, smaller doses (100-400
mg/kg) were well tolerated and could be given repeatedly. Apparently several rats
showed chronic inflammatory lung lesions with bronchiectasis (i.e. abnormal
dilatation of bronchi). Also interstitial hyperplasia was present in the testes of two
rats. However, similar chronic lung and kidney lesions were found among control
rats. Six of the exposed rats survived for more than 12 months after the last dose.
Of these, five developed tumours: one of the rats developed an interstitial cell
tumour of the testes, two developed squamous cell carcinomas of the jaw, and two
developed pituitary tumours. Similar pituitary tumours were found in the control
group. Testicular interstitial cell tumours and jaw tumours were reported to occur
occasionally in ageing control rats. The GBL used in this study was obtained by
distillation from an epoxy resin hardener consisting of 4,4´-diaminodiphenyl-
methane (142). The amount of 4,4´-diaminodiphenylmethane occurring together
with GBL in the distillate was not reported.
Ninety-five male NMRI mice received 750 mg/kg GBL orally once per week
for 18 months. There was no statistically significant difference in the incidences
of lymphomas and lung adenomas between exposed and untreated animals (68).
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No local tumours were observed in a group of 16 female Swiss-Webster mice
given a total of 12 subcutaneous injections of 0.005 mg GBL in 0.1 ml tricaprylin
three times a week for 4 weeks and observed for at least 18 months (151).
A 2-year gavage study was carried out according to the NTP protocol for
carcinogenicity testing (118). Groups of 50 F344/N rats and B6C3F1 mice of each
sex were given GBL in corn oil by gavage 5 days a week for up to 103 weeks
(Table 2, 3). Male rats received 0, 112, or 225 mg/kg body weight, female rats
received 0, 225, or 450 mg/kg body weight, and mice received 0, 262, or 525
mg/kg body weight. The mean body weight of high dose female rats was lower
than that of the controls. There was no evidence of carcinogenic activity of GBL
in male or female rats. In the female rat, negative trends were observed in the
incidences of cysts and fibroadenomas of the mammary gland, and in cysts of the
pituitary pars distalis. Decreased mean body weight and CNS depression were
noted shortly after exposure in the mice. There was equivocal evidence of
carcinogenic activity in male mice given 262 mg/kg. Increased incidences of
proliferative lesions, primarily hyperplasia, of the adrenal medulla in low-dose
male mice were associated with GBL exposure (pheochromocytoma, benign or
malignant: 2/48 controls, 6/50 low-dose, 1/50 high-dose; hyperplasia: 2/48
controls, 9/50 low-dose, 4/50 high-dose). The incidence of hepatocellular
neoplasms in exposed male mice was lower than that in the controls. The
sensitivity of the study in male mice to detect a carcinogenic effect was reduced
by a low survival of high dose males. There was no evidence of carcinogenic
activity in female mice (118).
In mice given repeated skin applications of one drop of a 1% solution of GBL
in acetone twice weekly for life, the incidence of lung tumour was 21/30 (70%)
compared with 9/17 (53%) in acetone-treated controls. No skin tumours were
observed (136). In newborn mice given subcutaneous injections of 1 µg GBL on
days 1, 4, and 8, 18/34 (53%) of the animals developed lung tumours whereas
27/44 (61%) of the controls had lung tumours (136).
Mice of both sexes were given 2 mg doses of GBL in 0.1 ml water (about 57
mg/kg) orally twice weekly for life. In treated mice, the average survival was 571
days compared with 595 days in untreated controls. In this case, the incidence of
lung tumours was 20/36 (55%) compared with 27/44 (61%) in untreated controls
(136).
Mice were painted on the clipped dorsal skin with 0.1 ml of a 10% solution of
GBL in benzene (which corresponds to about 330 mg/kg), three times weekly
during their total lifespan. Non-carcinogenic effects were not evaluated in this
study and no increase in tumour incidence above that observed in benzene-treated
controls was found (161). In a second study GBL was dissolved in acetone and
administered three times weekly for 495 days. No increase in tumour incidence
above controls was observed (162).
Mice of both sexes received a diet containing 1 000 mg GBL/kg of diet for life.
No increases in the incidence of mammary tumours in female mice (exposed:
19/30; untreated 43/61) or of hepatomas in male mice (exposed: 5/30; untreated
6/54) were observed (136).
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Male Wistar rats received subcutaneous injections of 2 mg GBL in Arachis
oil twice per week for 61 weeks and were observed up to 100 weeks. All rats
survived, and no tumours were observed (29).
Chemical structure combined with short-term genotoxicity and toxicity tests
has been used to predict carcinogenicity. Tennant and co-workers have predicted
that GBL is not a genotoxic carcinogen and is unlikely to be a non-genotoxic
carcinogen (153). King and Srinivasan have predicted that GBL is not a carcino-
gen based on molecular structure using inductive logic programming (82).
An overall evaluation of the carcinogenicity data shows that GBL in not an
experimental carcinogen in rats and mice.
10.5 Mutagenicity and genotoxicity
A large number of mutagenicity studies of GBL have been performed and data
thereof is described in several reviews (1, 18, 26, 71, 72, 118). Generally, in vitro
experiments with and without exogenous metabolism (S9) were performed. The
results of the in vitro and in vivo mutagenicity studies are summarised below. The
in vivo studies are described in more detail. The individual studies are listed in
Tables A1-A5 in Appendix 2.
GBL has been studied in several tests to detect a DNA damaging potential.
Such tests include an ADP-ribosyl transferase (ADPRT) mediated decrease in
NAD-content in human amnion FL cells without activation (38, 174), a lambda
induction assay with activation (154), a modified liquid suspension assay in
E. coli without activation (129), SOS chromotest in E. coli with and without
activation (107, 126), several differential toxicity tests in B. subtilis with and
without activation (59, 74, 78, 158), unscheduled DNA repair synthesis in HeLa
S3 cells with and without activation (102), DNA repair in Chinese hamster ovary
cells (deficient in nucleotide excision repair) without activation (69), and DNA
alkylation of calf thymus DNA without activation (65). The vast majority of these
tests were negative. A weak positive response was found in the modified liquid
suspension assay in one of the E. coli strains (129) and in one of the four differen-
tial toxicity tests when using fish S9 (78). Based on the overall results from these
tests for primary DNA damage, GBL is considered to be negative.
A large number of studies investigating possible gene mutations (reverse
mutation) in bacteria have been reported in the literature. Several test strains of
S. typhimurium, capable of detecting both base pair substitutions and frame shift
mutations (3, 8, 12, 50, 51, 63, 70, 73, 97, 112, 128, 135, 147, 156, 164), but also
strains of E. coli have been used (51, 103, 164). In all these studies GBL has
been tested both in the presence and absence of metabolic activation. GBL was
negative in all studies.
GBL has also been tested for cytogenetic and mutagenic effects in yeast. These
studies include tests for gene conversion (75, 143, 175), mitotic crossing-over
(79), reverse (109) and forward (94) mutations, and aneuploidy (122). Most of
the tests were performed with and without metabolic activation. The only positive
effect was found using the JD1 strain of S. cerevisiae and only when GBL was
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dissolved in dimethyl sulfoxide (DMSO) (not with ethanol) in the absence of
metabolic activation (143). Thus, GBL is considered not to elicit genotoxic effects
in yeast.
Studies on chromosomal damage in mammalian cells in vitro have given
conflicting results using GBL. In a study by Loveday and co-workers chromo-
somal aberrations and sister chromatid exchanges were reported in Chinese
hamster ovary cells, in the presence but not in the absence of an exogenous
metabolism system, at high concentrations (96). Such effects were not found using
Chinese hamster ovary cells (sister chromatid exchange) or rat liver RL1 cells
(chromosomal aberrations), at lower concentrations (27, 123). A negative result
was also obtained in an in vitro gene mutation test using a human fibroblast cell
line (HSC172). However, in this test no exogenous metabolism system was
included, whereas the other studies were conducted with and without activation.
No clear conclusions regarding genotoxic effects of GBL in mammalian cells can
be drawn from these experiments.
GBL gave positive results in a baby kidney hamster (BHK-21) cell oncogenic
transformation assay (Styles test) using growth in soft agar as the end point. This
study is well documented and the test includes auxiliary metabolism (S9) (150). In
another study also using BHK-21 cells (with and without metabolic activation),
and higher concentrations of GBL than in the Styles study, no increased rate of
morphological transformations was noted. However, in the last study positive
controls came out negative. In general, the usefulness of the cell transformation
assay in predicting carcinogenic effects of chemical is debated. Furthermore, an
evaluation of the Styles test has indicated that it is not very useful due to low
predictability. Thus, no conclusion can be drawn with respect to the ability of
GBL to induce morphological transformation in mammalian cells.
Tests for sex-linked recessive lethal mutations and mitotic recombination in
D. melanogaster following administration of GBL in feed (up to 2.8% in feed)
were negative (44, 118, 166, 167). GBL was also negative in two separate micro-
nucleus tests using bone marrow from mice. In the first study B6C3F1 mice were
given two consecutive intraperitoneal injections of 984 mg/kg body weight of
GBL (138) and in the second study CD-1 mice were administered two consecutive
intraperitoneal injections of 560 mg/kg of GBL (157). GBL was also negative in
other in vivo tests (mutagenicity and sperm morphology) using mice (121, 155).
Taken together these studies show that GBL does not express a mutagenic
potential in vivo at doses up to about 1 000 mg/kg body weight.
Based on all the above studies it is concluded that GBL is not mutagenic.
However, the possibility that GBL may cause chromosomal aberrations and sister
chromatid exchanges in vitro cannot be completely ruled out.
10.6 Reproductive and developmental effects
10.6.1 Fertility
No standard one- or two-generation fertility studies in experimental animals were
located in the open literature, either with GBL or GHB. Most repeated dose
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studies have not revealed toxic effects to the testes. However, one study showed a
reduced gonadal development resulting in significant reduced testicular weights in
rats exposed to GBL (see 10.6.2).
Proestrous serum LH level and ovulation were significantly reduced when GBL
in saline was injected intraperitoneally at doses from 62.5 to 750 mg/kg body
weight in 4-day cyclic female Sprague-Dawley rats just prior to the proestrous
critical period (Table 2) (10). A reduction in FSH was noted at doses of 500
mg/kg and higher. At this dose, increases in uterine wet weight accompanied the
increased incidence of uterine ballooning, but only the 750 mg/kg dose showed a
significant increase above controls. No change was noted in ovarian weight. The
antiovulatory effective dose in 50% of population (ED50) was approximately
250 mg/kg, which is a subanaesthetic dose. A reduction in the number of rats
ovulating was evident at 62.5 mg GBL/kg, with a 63% inhibition at 250 mg/kg.
A dose of 750 mg/kg blocked ovulation (10). This study indicates that GBL may
interfere with female reproduction. Additional studies, preferentially also in an
additional species, are needed to address the relevance of these findings to
humans.
GBL has been shown to almost totally block reversibly germinal vesicle
breakdown (i.e. inhibiting the first meiotic metaphase) in bovine oocytes in vitro
at a concentration of 100 µM (88). The relevance of this finding to human
reproduction is not clear.
10.6.2 Developmental toxicity
The possibility, that GBL might be embryotoxic and/or teratogenic was examined
in the rat (86, 87). GBL was administered by gavage on gestation days 6 through
15. The dose levels were 10, 50, 125, 250, 500, and 1 000 mg GBL/kg/day (10
rats per group). On day 21 the females were anaesthetised and the foetuses were
removed by Caesarean section. No significant differences were found between
the control group and the treated groups with regard to corpora lutea and total
implantation sites, alive and dead foetuses, resorptions, preimplantation and post-
implantation losses, or male/female ratios. No embryotoxic effects were seen (86,
87). No major soft tissue anomalies or skeletal defects were found. In the 500
mg/kg group a slight decrease in the incidence of bipartite centra of the thoracic
vertebrae was found. Furthermore, a slight increase in the frequency of unossified
hyoid cartilage was reported at 10 and 125 mg/kg. Foetal weight was, however,
significantly increased in rats given 50, 125, and 250 mg/kg compared to controls.
Placental weights were significantly reduced for all GBL treated animals. The
foetal skeletal alterations were not dose-dependent and were by the authors
considered not to be due to GBL exposure. These results indicate that oral
administration of GBL up to a dose of 1 000 mg/kg does not cause developmental
toxicity in rats.
Male Wistar rats (aged 21 days) were given free access to tap water containing
1% or 2% GBL (Table 2) (28). The corresponding doses of GBL were calculated
to be approximately 1 100 and 2 200 mg GBL/kg/day. In a second experiment,
animals were given 0.5% or 1.0% GBL. 0.5% (approximately 550 mg/kg) and
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higher was shown to reduce gonadal development resulting in significant reduced
testicular weights. Body weights were not affected in the rats exposed to 0.5% and
1.0% in the second experiment, but was reduced in the rats exposed to 1% and 2%
in the first experiment. The reduction in testicular weight was about 40% at 0.5%
GBL and about 50% at 1.0% GBL. The effect of GBL on testicular weight was
apparently not due to decreased feeding or to a generally smaller increase in body
weight. However, seminal vesicle weights and serum prolactin levels were similar
in the control rats and in the rats treated with GBL (28). The study is relatively
poorly reported, e.g. the exposure time is not stated. Based on treatment schedules
with other substances tested in the same study, an exposure time of 20-21 days is
assumed.
10.7 Other studies
No other relevant studies were available.
11. Observations in man
11.1 Acute effects
No reports were located describing effects following acute occupational exposure.
Our earlier knowledge of acute systemic effects in humans is based mainly on
poisonings after oral intake of GBL and its use as a drug. GBL and GHB have
been tested for therapeutical use in humans as a sedative and in the treatment of
alcohol dependency (GHB dose: 0.15 g, three times daily or 50 mg/kg body
weight, three times daily for 8 weeks) and the opiate withdrawal syndrome (1, 2,
36). GBL is also being used experimentally in the treatment of narcolepsy. GHB
has been under investigation for management of narcolepsy for about 2 decades
(dose: 4 g given twice during the night) (36, 141).
GBL is illegally marketed for many claimed purposes, including inducing sleep,
releasing growth hormone, enhancing sexual activity and athletic performance,
reliving depression, and prolonging life. The recent ever increasing use of GBL
and GHB by younger people as a drug and to some extent by athletes to increase
muscle mass, have given additional information on dose-effect relationships. The
most frequent intoxications with GHB result from its use as a drug, often together
with alcohol and other drugs and at peroral doses of 2-3 g (35 mg/kg body weight)
(36).
Acute toxic effects based on human cases include bradycardia, hypothermia,
CNS depression, prolonged unconsciousness (typically for 1-2 hours), confusion,
combativeness, obtundation, and uncontrolled movements, and are similar to
those seen in experimental animals (15, 16, 36, 118, 165, 173).
Manifestations of acute GHB toxicity include amnesia and hypotonia at dose
levels of 10 mg/kg body weight; a normal sequence of rapid eye movement
(REM) and non-REM sleep at 20-30 mg/kg body weight; and anaesthesia at 50
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mg/kg body weight. 50-70 mg/kg body weight may induce coma (15, 36, 124).
GBL is more potent than GHB and life threatening effects are likely to occur at
lower doses than with GHB (85). A lethal peroral dose of GHB has been sug-
gested to be in the order of 500 mg/kg body weight (124). The effects of GHB
on the CNS are potentiated by concomitant intake of alcohol and other central
stimulants such as amphetamine, ecstasy, and cocaine (36). Surgical anaesthesia
is obtained at a dose of approximate 60 mg/kg body weight (142). Euphoria has
been reported at dose levels of 20-30 mg/kg body weight (64).
In Scandinavia some cases of poisoning from GBL in children have been
reported after ingestion of small amounts (less than 8 ml) of GBL. GBL had a
narcotic effect after ingestion and caused unconsciousness rather rapidly (43). A
2-year-old boy was found unresponsive approximately 40 minutes after ingestion
of GBL used as a solvent to remove methacrylate glues. The patient was apneic,
bradycardic, and flaccid. Six hours after oral intubation, he was alert and
breathing spontaneously (67). Some additional case reports from Scandinavia
have been published. Two males in their twenties lost consciousness after
ingestion of 50 ml nail varnish containing 50% GBL and 50% ethanol. Brady-
cardia was observed and treated during the first hours, and the patients recovered
after a few hours (4). Coma, respiratory depression, and bradycardia were
reported in two cases of GBL poisoning following ingestion of a nail polish
remover (127).
More than 50 cases of GBL poisonings have been reported in USA (16). The
US Centers for Disease Control and Prevention (CDC), has described some cases
of GBL intoxication (16): A 24-years-old man vomited and had seizures shortly
after drinking 3-4 oz of Revivarant (80-105 mg GBL/kg body weight). A 46-year-
old women had a seizure and lost conscious after drinking approximately 2.7 oz
(70 mg GBL/kg body weight) of Revivarant in conjunction with ethanol. A 31-
year-old man drank approximately 1 oz (26 mg GBL/kg body weight) Revivarant,
four beers, and a large sip of wine. Shortly thereafter he gradually lost conscious-
ness. Two men (24- and 26-year-old) drank 10-13 oz (240-340 mg GBL/kg body
weight) Revivarant together with alcohol. Both men became unresponsive and
altered between somnolence and confusion.
In UK a near fatal GBL intoxication has been reported in a 44-year-old male
having ingested several hundred ml of a “health drink”-“Furumax Revitaliser”
containing 8 g/100 ml of GBL. An intake of 500 ml would correspond to approxi-
mately 570 mg/kg body weight (33). Shortly after, he became unconscious with
shaking of the limbs. Respiratory effort was poor and the patient required
additional oxygen.
In Italy an alveolar gas exchange impairment has been reported in a 4-year-old
child following ingestion, and perhaps also inhalation of chemical product
(Destak, paint remover solvent) containing GBL and may be due to a direct toxic
effect on the alveolar-capillary membrane (125). The child had a progressive
shortness of breath causing cyanosis and eventually respiratory failure. Chest x-
ray examination showed diffuse bilateral interstitial oedema and the absence of
cardic enlargement.
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11.2 Irritation
No published data on skin and eye irritation were found in the scientific literature.
11.3 Effects of repeated exposure on organ systems
No information addressing possible toxic effects on specific organ systems
following exposure to GBL was found. However, chronic use of GBL can lead to
several neurotoxic effects, including anxiety, depression, tremor, and insomnia
(66).
11.4 Genotoxic effects
No information describing genotoxic effects of GBL in humans was found.
11.5 Carcinogenic effects
Kogevinas and co-workers studied the incidence of non-Hodgkin’s lymphoma
and soft tissue sarcoma in two nested case-control studies in workers exposed to
phenoxy herbicides, chlorinated phenols, and dioxins (84). GBL was one of
several agents evaluated. The two studies were conducted within an international
cohort of workers. Odd ratios are based on cumulative exposure scores grouped in
four categories (non-exposed, low, medium and high exposure). One case of soft-
tissue sarcoma and one control were classified as exposed (odds ratio, 5.0; 95%
confidence interval (CI), 0.3-80). Two cases of non-Hodgkin’s lymphoma and
three controls were identified as exposed (odds ratio, 3.0; 95% CI, 0.50-18.1). The
results are based on few cases and exposure to many of the compounds examined
was highly correlated, complicating the identification of the effect of individual
chemicals. Thus, no conclusions can be drawn regarding the capability of GBL to
cause cancer in humans.
11.6 Reproductive and developmental effects
No human data were available on fertility and developmental toxicity.
12. Dose-effect and dose-response relationships
There are limited and uncertain data concerning dose-effect and dose-response
in humans following acute exposure. To our knowledge there are no human
repeated dose exposures that can be used to derive dose-effect or dose-response
relationships. Furthermore, almost exclusively all repeated dose exposures using
experimental animals occur by the oral route (feed, gavage, drinking water).
Manifestations of acute GHB toxicity include amnesia and hypotonia at dose
levels of 10 mg/kg body weight; a normal sequence of REM and non-REM sleep
at 20-30 mg/kg body weight; and anaesthesia at 50 mg/kg body weight. 50-70
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mg/kg body weight may induce coma (16, 36, 124). GBL is more potent than
GHB and life threatening effects are likely to occur at lower doses than with GHB
(85). A lethal peroral dose of GHB has been suggested to be in the order of 500
mg/kg body weight (124). The effects of GHB on the CNS are potentiated by
concomitant intake of alcohol and other central stimulants such as amphetamine,
ecstasy, and cocaine (36). Surgical anaesthesia is obtained at a dose of approxi-
mately 60 mg/kg body weight (142). Euphoria has been reported at dose levels of
20-30 mg/kg body weight (64).
Effects reported in experimental animals after single or repeated dose exposure
are presented in Table 2. Table 3 summarises the results in the carcinogenicity
study by NTP (118). No observed adverse effect level (NOAEL) values are given
whenever appropriate.
Repeated dose toxicity in rats at various dose levels and exposure durations has
been studied by NTP (118). Given daily oral bolus doses of GBL for 12 consecu-
tive days excluding weekends, rats exposed to 1 200 mg/kg body weight and day
all died, most likely due respiratory depression caused by effects on the CNS.
At 600 mg/kg/day one animal died, and no deaths were noted at lower doses.
Increasing the exposure period to 90 days resulted in deaths in all male rats and
one female at 900 mg/kg but no deaths at 450 mg/kg. No histopathological lesions
were seen in these studies. Besides a decreased body weight in female rats given
450 mg/kg for 2 years, exposed animals showed no signs of toxicity. In a similar
study in mice almost all animals died when exposed to 1 400 mg/kg for 12
consecutive days excluding weekends. An acute effect on the CNS was noted in
animals exposed to 350 mg/kg or more. In the 90-day study at a dose of 1 050
mg/kg/day, 30% of the males and 10% females died. In the dose-range from 65-
525 mg/kg body weight absolute and relative organ weights were not affected.
There were no gross or microscopic lesions. In mice exposed by gavage at dose
levels of 262 or 525 mg/kg/day for 2 years no other effects besides decreased
body weight and CNS depression shortly after exposure were noted. These studies
indicate that the CNS is the target organ for GBL. Although reduced weight gain
and relative and absolute weights have been reported in some organs, they seem
not to be target organs for GBL.
Two studies, both in rats, indicate that exposure to GBL may affect fertility. In
the first study, exposure of young male rats (21 days) to 0.5 and 1% in the
drinking water for 20 days resulted in 40 and 50% reductions in testicular weight,
respectively (28). In the second study, a marked inhibition in ovulation was noted
after a single intraperitoneal injection of GBL at a dose level of 250 mg/kg body
weight (10). The effect on ovulation was to be dose-dependent with a 22%
inhibition at 62.5 mg/kg body weight, 63% at 250 mg/kg body weight, 71% at 500
mg/kg body weight, and 100% at 750 mg/kg body weight. No effects on the testes
were reported in the NTP studies at even higher doses (118). Thus it seem that
young immature male rats are especially sensitive to gonadal toxicity caused by
GBL (e.g. GBL affects hormonal-dependent testicular development) or that
differences in kinetics between a bolus dose of GBL and a more steady intake of
the same dose from drinking water affects its toxicodynamic potential.
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NTP has studied the carcinogenic potential of GBL in rats and mice (118).
There is no evidence that GBL is an experimental carcinogen in rats or in female
mice. In male mice there was an increased incidence of benign or malignant
pheochromocytoma in the low-dose group but not in the high-dose group.
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13. Previous evaluations by (inter)national bodies
GBL has been evaluated for carcinogenicity by International Agency for Cancer
Research (IARC) in 1976 and 1999 (71, 72). In 1999, IARC concluded that there
is inadequate evidence in human for the carcinogenicity of GBL and there is
evidence suggesting lack of carcinogenicity of GBL in experimental animals (72).
The overall evaluation of GBL is not classifiable as to its carcinogenicity to
humans (group III).
14. Evaluation of human health risks
14.1 Groups at extra risk
Since there is no relevant occupational exposure data, no groups at specific risk
can be identified. In the general population, people using GBL as a drug and often
together with ethanol and other drugs are at high risk.
14.2 Assessment of health risks
The toxicological information on GBL is limited, especially in humans but also
in experimental systems. In general, most of the classical toxicological studies
with GBL (and GHB) are old and often lack detailed information regarding
experimental design and an evaluation of the results. The uptake, distribution,
metabolism, and excretion in humans are likely to be similar to that observed in
experimental animal. GBL is rapidly and complete transformed to GHB once
taken up into the body. Toxicity data for GHB are also relevant in the risk
assessment of GBL.
The anaesthetic effects resulting from acute oral GBL exposure are well
documented in humans as well as in experimental animals. Acute toxic effects
based on human intoxications include bradycardia, hypothermia, CNS depression,
prolonged unconsciousness (typically for 1-2 hours), confusion, combativeness,
odtundation, and uncontrolled movements. The effects of GHB are dose-
dependent: amnesia and hypotonia at dose levels of 10 mg/kg body weight; a
normal sequence of REM and non-REM sleep at 20-30 mg/kg body weight; and
anaesthesia at 50 mg/kg body weight. 50-70 mg/kg body weight of GHB may
induce coma. GBL is more potent than GHB and life threatening effects are likely
to occur at lower doses than with GHB. The dose-response curve varies between
humans and the dose levels given above for the various effects should be
considered as approximate levels. The effects of GHB on the CNS are potentiated
by concomitant intake of alcohol and other drugs such as amphetamine, ecstasy,
and cocaine.
Eye irritation from GBL exposure has been quoted in several publications,
however, the original data was not available for scrutiny. In rabbits, eye irritation
has been reported in a study where GBL was instilled into the conjunctival sac.
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The damage to the cornea and iris were completely reversible after 14 days.
Findings in in vitro tests for eye irritation support the eye irritation noted in
animals. It is concluded that GBL has the potential to cause eye irritation in
humans.
Conflicting results have been obtained in skin irritation studies in animals and
humans. The data do not allow a clear conclusion regarding skin irritation in
humans. However, there are some indications that GBL may act as a weak skin
irritant.
The very limited information on possible skin sensitisation does not allow a
conclusion to be drawn at present.
No studies using repeated inhalation or dermal exposure were located. In
several oral repeated dose studies of varying length in mice and rats no overt signs
of general toxicity, organ toxicity, or histopathological changes were noted. High
doses (> 600-900 mg/kg body weight in rats; >1 000 mg/kg body weight in mice)
were lethal. The toxic effects noted were those of anaesthesia at doses > 250-300
mg/kg body weight and reduced body weight gain. A NOAEL of 225 mg/kg body
weight/day based on reduced weight gain in male rats in the carcinogenicity
bioassay is proposed.
No reports on genotoxicity in humans are available. GBL has been extensively
tested for genotoxic effects in experimental systems. None of the in vivo studies
were positive. The only positive results are in one study for gene conversion in
yeast, a cell transformation assay and in one test for sister chromatid exchange
and chromosomal aberrations. Based on all available genotoxicity studies, GBL
should be regarded as non-genotoxic.
The carcinogenic potential of GBL has been studied in several experiments in
rats and mice. The most recent study and also that of best scientific quality (118),
indicates that GBL is not carcinogenic following oral administration. The NTP
study report stated that there were equivocal evidence of carcinogenicity at one
dose level in male mice and that the sensitivity of the study to detect an effect in
male mice was reduced due to low survival in the high-dose group. Furthermore,
the use of different structure-activity models to predict carcinogenicity lends no
support for a carcinogenic or mutagenic potential for GBL. An evaluation by
IARC in 1999 has concluded that GBL is not classifiable as to its carcinogenicity
to humans (72).
No standard fertility studies are available. However, GBL has affected pro-
estrous LH and FSH levels and ovulation in rats (ED50 approx. 250 mg/kg body
weight) and a dose-dependent reduction in the number of rats ovulating were
detected from 62.5 mg/kg body weight. 0.5% GBL (approximately 550 mg/kg
body weight) in drinking water led to reduced testicular weight in young rats. The
effects observed in male and female rats exposed to GBL could result in reduced
fertility in adults and in young male rats exposed postnatally. No effects on
development were detected when rats were orally exposed to GBL.
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14.3 Scientific basis for an occupational exposure limit
The database for deriving occupational limits for GBL is limited. The most
relevant human occupational exposure routes are likely to be by inhalation or
through dermal contact. Almost all experimental studies have, however, used oral
exposure. Furthermore, information on occupational exposure levels is lacking.
The critical effects of GBL are:
− Narcotic and anaesthetic effects: Sedative and hypnotic effects similar to those
observed in experimental animals have been seen in humans. Based on human
oral exposure, effects on the CNS are evident at dose levels of approximately
10-50 mg GHB/kg body weight.
− Animal studies indicate that GBL exposure could adversely affect fertility.
Reduced ovulation was found in GBL-exposed dams at the lowest tested single
dose of 62.5 mg/kg body weight.
15. Research needs
Occupational surveys are needed to clarify current levels of GBL exposure in the
work place air and identify specific operations that could lead to high exposures or
parts of the work force that are at risk.
Data from toxicokinetic studies using inhalation exposure would facilitate an
extrapolation of toxicity from the oral route to that of inhalation. Likewise, acute
and repeated dose toxicity studies using inhalation exposure would help in
evaluating any direct or systemic effects of GBL on the respiratory system and be
helpful when setting occupational exposure limits. From a classification point of
view, an up to date eye irritation and skin sensitisation study would be helpful and
would assist in assessing such risks to humans. The indication that GBL exposure
may affect testicular development and ovulation could suggest a possible altered
fertility. Accordingly, a two-generation fertility study would be needed.
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16. Summary
Søderlund E. The Nordic Expert Group for Criteria Documentation of Health
Risks from Chemicals. 135. γ-Butyrolactone (GBL). Arbete och Hälsa
2004;7:1-49.
γ-Butyrolactone (GBL) is used as an intermediate for the production of other
chemicals, as a solvent, and as a binder in foundry. Non-occupational use results
from its natural occurrence in fruits and berries, its use as an experimental drug in
treatment of alcohol withdrawal symptoms and narcolepsy. Due to its euphoric/
hallucinogenic properties the abuse of GBL and γ-hydroxybutyrate (GHB) has
increased dramatically in several countries.
GBL is a colourless oily liquid with a mild caramel odour. It has a relatively
low vapour pressure, a boiling point of 206ºC, and is miscible with water.
Little information is available regarding occupational exposure. In the USA in
1981-1983 it has been estimated that over 40 000 workers were potentially
exposed and of these about 2/3 are exposed in printing and publishing and in
textile mill industries.
GBL is easily absorbed after ingestion and to some extent also absorbed
through the skin. The enzymatic hydrolysis to GHB in the body is rapid and
extensive. GBL is distributed to all organs mainly as GHB. The latter is further
metabolised by catabolic enzymes, and finally eliminated as CO2 and urinary
metabolites.
GBL has a low to moderate acute toxicity in experimental animals and causes
CNS depression both in humans and animals. GBL causes eye irritation in rabbits,
whereas no conclusions can be drawn regarding sensitisation. Repeated oral doses
of approximately 1 000 mg/kg body weight/day caused death in mice and rats. No
toxic effects, apart from reduced weight gain, were elicited at lower doses. An
overall evaluation of an extensive database for genotoxicity indicates that GBL is
not genotoxic. There is no support for a carcinogenic effect in experimental
animals. An evaluation for carcinogenicity by IARC in 1999 concluded that GBL
is not classifiable as to its carcinogenicity in humans. GBL might affect testicular
development in young rats and may reduce or block ovulation in adult rats.
There is a need for identifying occupational exposure levels and additional
toxicological information regarding acute local and reproductive effects.
Based on available data CNS depression is considered the critical effect from
GBL exposure. Reproductive toxicity (reduced ovulation) found in animals cannot
be fully assessed with respect to human health at present.
Keywords: carcinogenicity, CNS effects, gamma-butyrolactone, genotoxicity,
irritation, metabolism, occupational exposure limits, reproductive toxicity.
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17. Summary in Norwegian
Søderlund E. The Nordic Expert Group for Criteria Documentation of Health
Risks from Chemicals. 135. γ-Butyrolactone (GBL). Arbete och Hälsa
2004;7:1-49.
γ-Butyrolakton (GBL) benyttes som mellomprodukt i produksjon av andre
kjemikalier, som løsningsmiddel og som bindemiddel i støpesand. Ikke-
yrkesmessig eksponering vil kunne finne sted fordi stoffet forekommer i naturlig i
frukt og bær, benyttes i eksperimentell medisinsk behandling av abstinens knyttet
til bruk av alkohol og narkolepsi. GBL og γ-hydroxibutyrat (GHB) har i den
senere tid hatt en kraftig økning i bruken på det illegale markedet som narkotisk
stoffer som gir hallusinasjoner og eufori.
GBL er en fargeløs oljeaktig væske med karamellaktig lukt. Det har et relativt
lavt damptrykk, et kokepunkt på 206oC og er blandbart med vann.
Det finnes lite informasjon om yrkeseksponering. I USA er det beregnet at
40 000 arbeidere kan tenkes å være eksponert og 2/3 av disse er eksponert i
industrier som driver med trykking og publisering og i tekstilindustrien.
GBL tas lett opp i kroppen etter svelging og i mindre grad gjennom huden.
Enzymatisk hydrolyse til GHB foregår raskt og nesten fullstendig i kroppen og
stoffet fordeles til alle organer hovedsakelig som GHB. Stoffet metaboliseres
videre via kroppens normale nedbrytningsenzymer og utskilles som CO2 via
utåndingsluften og som metabolitter i urin.
GBL har en lav til moderat akutt toksisitet i forsøksdyr og fører til effekter på
sentralnervesystemet både hos mennesker og dyr. GBL er øyeirriterende hos
kanin. Det er ikke mulig å konkludere om stoffet kan føre til hudallergi. Gjentatt
oral eksponering for doser i størrelsesorden 1 000 mg/kg kroppsvekt/dag medførte
dødsfall hos mus og rotter. Ingen toksiske effekter, bortsett fra redusert økning i
kroppsvekt, er funnet ved lavere doser. En vurdering av alle studier av genitoksi-
sitet tyder på at stoffet ikke gir denne type skader. Det finnes ikke holdepunkter
for at stoffet er kreftfremkallende i dyreforsøk. En evaluering foretatt av IARC
i 1999 konkluderte med at GBL ikke lar seg klassifisere som mulig humant
karsinogen. GBL ser ut til å kunne påvirke utvikling av testikler hos unge rotter
og å redusere eggløsning hos voksne rotter.
Det trengs opplysninger om nivåer av GBL ved yrkeseksponering og ytterligere
toksikologisk informasjon angående akutte lokale effekter og effekter på
reproduksjon.
Basert på tilgjengelig toksikologisk informasjon er den kritiske effekten av
GBL en påvirkning av sentralnervesystemet. Det foreligger data fra dyreforsøk
som tyder på at GBL kam føre til redusert fertilitet. Det er imidlertid ikke på det
nåværende tidspunkt mulig å foreta en endelig vurdering av i hvilken grad GBL
kan føre til reproduksjonstoksisitet hos mennesker.
Nøkkelord: CNS effekter, gamma-butyrolakton, gentosisitet, irritasjon,
karsinogenitet, metabolisme, reproduksjonstoksisitet, yrkeshygieniske
grenseverdier.
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Appendix 1
The Danish Occupational Inspectorate list a tentative limit value of 50 ppm for
GBL in their list of organic solvents (6).
In Russia a hygienic standardisation of GBL in the air at populated sites is
reported (145). The 24-hour mean limit value is set to 0.1 mg/m3 (0.028 ppm).
This limit value appears to be based on the threshold concentration for GBL in
air being 0.51 mg/m3 following chronic exposure.
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TA
98
, T
A
10
0 
an
d 
TA
15
35
, r
ev
er
se
 m
ut
at
io
n
–
–
0.
1-
50
 µ
m
ol
/p
la
te
(95
)
S.
 ty
ph
im
ur
iu
m
 
TA
98
, T
A
10
0 
an
d 
TA
10
2,
 re
ve
rs
e m
ut
at
io
n
–
–
13
.0
 n
m
ol
-1
.3
 m
m
ol
/p
la
te
(3)
S.
 ty
ph
im
ur
iu
m
 
TA
98
, T
A
15
35
 an
d 
TA
15
37
, r
ev
er
se
 m
ut
at
io
n 
(fl
uc
tua
tio
n t
est
)
–
–
10
-1
 0
00
 µ
g/
m
l
(51
)
S.
 ty
ph
im
ur
iu
m
 
TA
98
, T
A
10
0,
 1
53
5 
an
d 
TA
15
37
, r
ev
er
se
 m
ut
at
io
n
–
–
10
 0
00
 µ
g/
pl
at
e
(63
)
E.
 c
ol
i W
P2
ur
vA
, r
ev
er
se
 m
ut
at
io
n 
(fl
uc
tua
tio
n t
est
)
–
–
10
-1
 0
00
 µ
g/
m
l
(51
)
E.
 c
ol
i W
P2
 a
nd
 W
P2
ur
vA
, r
ev
er
se
 m
ut
at
io
n
–
–
0.
5-
50
0 
µg
/p
la
te
(16
4)
E.
 c
ol
i W
P2
ur
vA
 a
nd
 W
P2
ur
vA
/p
K
M
10
1,
 re
ve
rs
e 
m
ut
at
io
n
–
–
N
ot
 g
iv
en
(10
3)
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W
ith
ou
t e
xo
ge
no
us
m
et
ab
ol
ic
 sy
ste
m
W
ith
 e
xo
ge
no
us
m
et
ab
ol
ic
 sy
ste
m
N
T,
 n
ot
 te
ste
d;
 +
, p
os
iti
ve
 e
ffe
ct
; (
+)
, w
ea
k p
os
itiv
e e
ffe
ct;
 –,
 no
 ef
fec
t.
S.
 c
er
ev
isi
ae
 
D
4,
 g
en
e 
co
nv
er
sio
n
–
–
0.
33
-3
33
.3
 µ
g/
pl
at
e
(75
)
S.
 c
er
ev
isi
ae
 T
1 
an
d 
T2
 (“
ra
ce
 X
II
”)
, m
ito
tic
 c
ro
ss
in
g-
ov
er
 (h
om
oz
yg
os
is 
by
 m
ito
tic
re
co
m
bi
na
tio
n,
 a
de
2 
lo
cu
s)
–
–
1 
00
0 
µg
/m
l
(79
)
S.
 c
er
ev
isi
ae
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1,
 g
en
e 
co
nv
er
sio
n
+
 
 
w
ith
 D
M
SO
–
 
 
w
ith
 e
th
an
ol
N
T
50
0 
or
 7
50
 µ
g/
m
l
(14
3)
S.
 c
er
ev
isi
ae
 
D
T,
 m
ito
tic
 g
en
e 
co
nv
er
sio
n
N
T
–
2 
25
0 
µg
/m
l
(17
5)
S.
 c
er
ev
isi
ae
 
X
V
18
5-
14
C,
 re
ve
rs
e m
ut
at
io
n
–
?
(22
.2
-2
22
) µ
l x
 1
0-
3 /m
l
(10
9)
S.
 p
om
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, f
or
w
ar
d 
m
ut
at
io
n
–
–
5-
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 µ
g/
m
l
(94
)
S.
 c
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ev
isi
ae
 
D
6,
 m
ito
tic
 an
eu
pl
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d
–
–
1 
00
0 
µg
/m
l
(12
2)
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W
ith
ou
t e
xo
ge
no
us
m
et
ab
ol
ic
 sy
ste
m
W
ith
 e
xo
ge
no
us
m
et
ab
ol
ic
 sy
ste
m
N
T,
 n
ot
 te
ste
d;
 +
, p
os
iti
ve
 e
ffe
ct
; (
+)
, w
ea
k p
os
itiv
e e
ffe
ct;
 –,
 no
 ef
fec
t.
Ch
in
es
e 
ha
m
ste
r o
va
ry
 (C
HO
) c
ell
s, 
ch
rom
os
om
al 
ab
err
ati
on
s
–
+
2 
58
0 
µg
/m
l
(96
)
Ch
in
es
e 
ha
m
ste
r o
va
ry
 (C
HO
) c
ell
s, 
sis
ter
 ch
rom
ati
d e
xc
ha
ng
e
–
+
3 
01
0 
µg
 /m
l
(96
)
Ch
in
es
e 
ha
m
ste
r o
va
ry
 (C
HO
) c
ell
s, 
sis
ter
 ch
rom
ati
d e
xc
ha
ng
e
–
–
1 
00
0 
µg
/m
l
(12
3)
R
at
 li
ve
r R
L 1
 
ce
lls
, c
hr
om
os
om
al
 a
be
rra
tio
ns
–
N
T
25
0 
µg
/m
l
(27
)
H
um
an
 fi
br
ob
la
st 
H
SC
17
2 
ce
ll 
lin
e,
 g
en
e 
m
ut
at
io
n,
 d
ip
ht
he
ria
 to
xi
n 
re
sis
ta
nc
e
–
–
50
0 
µg
/m
l
(61
)
B
ab
y 
ha
m
ste
r k
id
ne
y 
ce
lls
 (B
HK
 21
 C
13
/H
RC
 1)
, c
ell
 tr
an
sfo
rm
ati
on
–
–
8 
00
0 
(-S
9),
 1 
80
0 (
+S
9) 
µg
/m
l
(24
)
B
ab
y 
ha
m
ste
r k
id
ne
y 
ce
lls
 (B
HK
-21
), c
ell
 tr
an
sfo
rm
ati
on
N
T
+
25
-2
50
 µ
g/
m
l
(15
0)
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5.
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 v
iv
o 
te
st
s.
Te
st
 sy
ste
m
R
es
ul
ts
D
os
e
 
 
 
 
R
ef
er
en
ce
N
T,
 n
ot
 te
ste
d;
 +
, p
os
iti
ve
 e
ffe
ct
; (
+)
, w
ea
k p
os
itiv
e e
ffe
ct;
 –,
 no
 ef
fec
t.
D
ro
so
ph
ila
 m
el
an
og
as
te
r, 
se
x
-li
nk
ed
 re
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ss
iv
e 
le
th
al
 m
ut
at
io
ns
–
0.
2%
 in
 fe
ed
(16
6)
D
ro
so
ph
ila
 m
el
an
og
as
te
r, 
se
x
-li
nk
ed
 re
ce
ss
iv
e 
le
th
al
 m
ut
at
io
ns
–
2.
0-
2.
8%
 (2
0 0
00
-28
 00
0 p
pm
) i
n f
ee
d
(11
8)
D
ro
so
ph
ila
 m
el
an
og
as
te
r, 
in
te
rc
hr
om
os
om
al
 m
ito
tic
 re
co
m
bi
na
tio
n
–
0.
43
 o
r 0
.8
6 
%
 (5
0 o
r 1
00
 m
M
) i
n f
ee
d
(16
7)
B
6C
3F
1 
m
o
u
se
 b
on
e-
m
ar
ro
w
 c
el
ls,
 m
ic
ro
nu
cl
eu
s t
es
t
–
98
4 
m
g/
kg
 ip
 x
 2
(13
8)
CD
-1
 m
ou
se
 b
on
e-
m
ar
ro
w
 c
el
ls,
 m
ic
ro
nu
cl
eu
s t
es
t
–
56
0 
m
g/
kg
 ip
 x
 2
(15
7)
M
ou
se
 te
st
ic
ul
ar
 c
el
ls,
 fl
ow
 c
yt
om
et
ry
, m
ut
ag
en
ic
ity
 te
sti
ng
, i
nc
re
as
ed
 p
or
tio
n 
of
 d
ip
lo
id
 sp
er
m
–
10
0-
40
0 
m
g/
kg
 b
od
y 
w
ei
gh
t
(12
1)
N
M
RI
-m
ic
e,
 D
N
A
 fl
ow
 c
yt
om
et
ric
 m
ea
su
re
m
en
ts,
 m
ut
ag
en
ic
ity
 te
sti
ng
–
N
ot
 g
iv
en
(12
0)
(C
BA
 x 
BA
LB
/c)
F1
 m
ice
, s
pe
rm
 m
o
rp
ho
lo
gy
–
11
2–
1 
12
0 
m
g/
kg
 
ip
 
x
 5
(15
5)
